[Table_ReportDate] 2025 年 06 月 09 日 [Table_Author] 分析师：李时樟 执业证书：S1030522060001 电话：18065826333 邮箱：lisz@csco.com.cn 分析师：罗晴 执业证书：S1030524110001 电话：13603091122 邮箱：luoqing@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 TMT [Table_Title] 海外算力与应用迎来新催化 TMT 行业周报（6 月第 1 周） [Table_S 行业观点： ummary] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_ReportType] [Table_BaseData] 1) 周度市场回顾。TMT 板块内一级行业上周（6/03-6/06）涨跌 幅为：通信（5.27%）、电子（3.60%）、计算机（2.79%）、 传媒（2.59%），TMT 板块整体跑赢沪深 300（0.88%）。TMT 板 块内涨幅靠前的三级子行业分别为印制电路板（9.89%）、通 信网络设备及器件（8.33%）、通信应用增值服务（6 ...

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the innovation drug sector, particularly regarding the international expansion of domestic innovative drugs [3][4]. Core Insights - The report highlights the continuous rise in the enthusiasm for innovative drugs going overseas, with significant collaborations such as the $9 billion partnership between Bristol-Myers Squibb and BioNTech for the development of a PD-L1/VEGF dual antibody [3][4]. - It notes that the domestic innovative drug pipeline is becoming increasingly competitive on a global scale, with a long-term positive outlook for the internationalization of innovative drugs [3][4]. - The report also discusses the recent peak of COVID-19 cases in China, with a positivity rate of 23.8% reported at the end of May, indicating a need for continued monitoring [3][4]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming compared to the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both saw a rise of 2.89%, while in vitro diagnostics increased by 2% [10]. - Notable stock performances included Yiming Pharmaceutical with a 33.1% increase, while *ST Longjin experienced a significant decline of 36.3% [12]. Industry News and Key Company Announcements - Significant events include the presentation of clinical data for IBI363 by Innovent Biologics at the ASCO conference, showing promising efficacy in treating advanced non-small cell lung cancer [12][13]. - Stone Pharmaceutical received approval for its adenosylcobalamin capsules, expanding its product line in the blood and nervous system treatment areas [13]. - CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor, filling a gap in the treatment of cervical cancer in China [13]. - The report also mentions various other approvals and collaborations among companies, indicating a vibrant and active industry landscape [13][14].

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Viewpoints - The "old-for-new" policy in the gold and jewelry sector is expected to drive a transformation towards "self-indulgent" jewelry consumption. This policy will lower costs for consumers and stimulate demand, particularly among women aged 30-50 for fashionable gold jewelry [2][4] - The domestic tourism market during the Dragon Boat Festival showed a slight increase in travel volume and spending, indicating a recovery trend. However, the overall tourism consumption data was relatively flat, with future policies expected to boost demand [4][15] - The report highlights the performance of various consumer sectors, with notable stock price increases in food and beverage, home appliances, and textile sectors, while some companies experienced declines [4][13][14] Summary by Sections Market Weekly Review - The consumer sector showed mixed performance post-Dragon Boat Festival, with social services and textile sectors leading in growth [4] - Specific stocks such as Junyao Health and Springlight Technology saw significant increases of 24.43% and 28.79% respectively, while companies like Kuaijishan and Midea Group faced declines [4][13][14] Industry News and Key Company Announcements - The report mentions a significant increase in summer travel demand, with a 70% rise in travelers compared to last year, indicating a strong recovery in the tourism sector [15][16] - Companies like Suning and Anta Sports reported substantial sales growth during the holiday period, driven by consumer enthusiasm for new products and promotional activities [15][16] - The report also notes various corporate announcements, including acquisitions and stock sales, which may impact market dynamics [16][18]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides insights into the performance of various sectors within the equipment manufacturing industry, indicating a mixed outlook for different segments [1][7]. Core Insights - The domestic engineering machinery market is experiencing a short-term decline in activity, with May 2025 data showing a 3.86% year-on-year decrease in average working hours and a 5.01 percentage point drop in operating rates [2][10]. - The automotive sector shows resilience, with a 6% year-on-year increase in daily retail sales of passenger cars during the last week of May 2025, supported by promotional strategies from manufacturers [2][10]. - In the photovoltaic sector, prices for battery cells and modules have stabilized, but demand remains weak, particularly for photovoltaic glass, which is experiencing price declines due to reduced purchasing from downstream component manufacturers [2][10]. Summary by Sections Market Overview - From June 3 to June 6, 2025, the indices for machinery equipment, power equipment, and automotive sectors changed by 0.93%, 1.38%, and 0.17% respectively, ranking 19th, 14th, and 25th among 31 primary industries [7][10]. Industry News and Key Company Announcements - As of April 2025, China's renewable energy generation capacity reached 2.017 billion kilowatts, a 58% year-on-year increase, with wind, solar, and nuclear power surpassing thermal power capacity [2][18]. - A humanoid robot manufacturer has completed a Series A financing round exceeding 100 million RMB, indicating growing investment in robotics [2][18]. - China National Power Engineering Group signed a 1GW project order in Azerbaijan, highlighting international expansion in renewable energy projects [2][20].

Investment Rating - The report does not explicitly state an investment rating for the industry, but it provides insights into the performance of various sectors within the equipment manufacturing industry, indicating a mixed outlook for different segments [1][2]. Core Insights - The domestic engineering machinery market is experiencing a short-term decline in activity, with May 2025 data showing a 3.86% year-on-year decrease in average working hours and a 5.01 percentage point drop in operating rates [2]. - The automotive sector shows resilience, with a 6% year-on-year increase in daily retail sales of passenger vehicles in late May 2025, supported by promotional strategies from manufacturers [2]. - The photovoltaic sector is facing challenges, with a slowdown in demand for solar glass and a general decline in prices for various products, indicating a weak market outlook [2]. Summary by Sections Market Overview - From June 3 to June 6, 2025, the indices for machinery equipment, power equipment, and automotive sectors changed by 0.93%, 1.38%, and 0.17% respectively, ranking 19th, 14th, and 25th among 31 primary industries [7][10]. Engineering Machinery - The average working hours for major engineering machinery products in May 2025 were 84.5 hours, down 3.86% year-on-year and 6.25% month-on-month. The operating rate was 59.5%, reflecting a 5.01 percentage point year-on-year decline [2]. Automotive Sector - In the last week of May 2025, the average daily retail sales of passenger vehicles reached 95,000 units, a 6% increase compared to the same period last year, although it represented a 7% decrease from the previous month [2]. Photovoltaic Sector - The prices of photovoltaic cells and modules have seen a slowdown in their decline, but overall demand remains weak, particularly for solar glass, which is experiencing price pressure due to reduced purchasing needs from downstream component manufacturers [2]. Industry News - As of April 2025, China's renewable energy generation capacity reached 2.017 billion kilowatts, a 58% year-on-year increase, with wind, solar, and nuclear power surpassing thermal power capacity for the first time [2].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it indicates a positive outlook on the global competitiveness of domestic innovative drugs and the trend of innovative drugs going abroad [3][4]. Core Viewpoints - The innovative drug sector is experiencing a surge in overseas collaboration, highlighted by the partnership between Bristol-Myers Squibb and BioNTech to jointly develop a PD-L1/VEGF dual antibody with a total package worth $9 billion [3][4]. - The report notes that the recent ASCO conference showcased significant advancements in dual antibodies and ADCs, indicating a differentiated layout in early clinical stages for domestic innovative drugs [3][4]. - The report mentions a peak in the current COVID-19 wave, with a positivity rate of 23.8% reported at the end of May, which is higher than the entire year of 2024, although it has started to decline slightly [3][4]. Weekly Market Review - The pharmaceutical and biotechnology sector rose by 1.13% from June 3 to June 6, underperforming the Wind All A index, which increased by 1.61% [9][10]. - Among sub-sectors, raw materials and blood products both increased by 2.89%, while in vitro diagnostics rose by 2% [9][10]. - Notable stock performances included Yiming Pharmaceutical with a rise of 33.1%, Wanbangde at 32.6%, and Anglikang at 30.3%, while *ST Longjin fell by 36.3%, Huason Pharmaceutical by 12.4%, and Maipu Medical by 9.3% [12][10]. Industry News and Key Company Announcements - On June 4, Innovent Biologics reported promising Phase I clinical data for IBI363 in treating advanced non-small cell lung cancer at the ASCO annual meeting [12][13]. - On June 6, CSPC announced that its adenosylcobalamin capsules received drug registration approval from the National Medical Products Administration [13][14]. - On June 5, CanSino Biologics announced the approval of a new indication for its PD-1/CTLA-4 inhibitor in first-line treatment for cervical cancer [13][14]. - On June 2, Bristol-Myers Squibb and BioNTech announced a collaboration to develop the PD-L1/VEGF dual antibody BNT327, with a significant financial commitment involved [13][14].

Macroeconomic Overview - The May PMI indicates persistent weakness in domestic demand, with the manufacturing PMI at 49.5%, up 0.5 percentage points from the previous month, while the non-manufacturing PMI decreased to 50.3%, down 0.1 percentage points[22] - April industrial profits showed a year-on-year increase of 1.4%, with a 3.0% growth in April alone, reflecting some structural highlights despite overall economic challenges[11] Market Dynamics - The stock market experienced a slight decline with a weekly average trading volume of 1,093.9 billion CNY, down 79.4 billion CNY from the previous week, and the Shanghai Composite Index fell by 0.03%[10] - The bond market showed slight fluctuations, with the 10-year government bond yield rising by 0.85 basis points, indicating ongoing pressure on long-term funding despite a stable short-term liquidity outlook[10] Trade and Policy Impacts - Recent U.S. trade policies, including new restrictions on AI chip exports to China, have limited market optimism, with expectations for further negotiations diminishing[1] - The U.S. International Trade Court's ruling on Trump's tariffs initially boosted market sentiment, but subsequent court actions led to renewed market weakness, highlighting the volatility in trade relations[1] Profitability Insights - April's profit growth of 2.6% compared to March reflects a 0.4 percentage point rebound, primarily driven by the "two new" policies benefiting the midstream equipment manufacturing sector[11] - The Producer Price Index (PPI) is expected to continue its downward trend, with May's decline potentially widening, indicating ongoing pressure on profit margins[13] Risk Factors - Key risks include potential further deterioration in U.S.-China trade relations and weaker-than-expected economic fundamentals, which could exacerbate existing market vulnerabilities[1]

Investment Rating - The report provides a positive outlook on the pharmaceutical and biotechnology sector, highlighting a weekly increase of 2.21%, outperforming the Wind All A index and the CSI 300 index [2][7]. Core Insights - The report emphasizes the impressive performance of domestic innovative drugs at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, with over 70 oral presentations and more than 10 significant studies, indicating a growing participation of domestic innovative drugs [2][10]. - The report notes significant advancements in dual antibodies and ADC fields, with new mechanisms and targets emerging, suggesting a differentiated layout in early clinical stages [2][10]. - The report recommends focusing on early differentiated directions in anti-tumor drugs and long-term attention on biotech and traditional pharmaceutical companies deeply involved in dual antibodies and ADCs [2][10]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 2.21% from May 26 to May 30, outperforming the Wind All A index (-0.02%) and the CSI 300 index (-1.08%) [7]. - The best-performing sub-sectors included other biological products (4.65%), chemical preparations (4.27%), and medical research outsourcing (4.0%), while offline pharmacies saw a decline of 2.69% [7][8]. - Notable individual stock performances included Shuyou Shen (60.4%), Huason Pharmaceutical (42%), and Changshan Pharmaceutical (35.9%) [10]. Industry News and Key Company Announcements - On May 30, Summit Therapeutics announced positive results from the global Phase III clinical trial of the dual antibody Ivorosi, achieving the primary endpoint of progression-free survival (PFS) [10][12]. - The report highlights the collaboration between Xinnuo Wei Pharmaceutical and Astellas for the development of a new generation antibody-drug conjugate, with an upfront payment of $130 million and potential milestone payments totaling up to $1.34 billion [12][13]. - The report also mentions various companies receiving approvals for innovative drugs and therapies, indicating a vibrant pipeline in the industry [14][15].

Investment Rating - The report provides a positive outlook on the pharmaceutical and biotechnology sector, highlighting a 2.21% increase in the sector, outperforming the Wind All A index and the CSI 300 index [2][7]. Core Insights - The report emphasizes the impressive performance of domestic innovative drugs at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, with over 70 oral presentations and more than 10 significant studies, indicating a growing participation of domestic innovative drugs [2][10]. - The report recommends focusing on early differentiated directions in anti-tumor drugs and long-term investments in biotech and traditional pharmaceutical companies that are deeply engaged in bispecific antibodies and antibody-drug conjugates (ADCs) [2][10]. - The report discusses the successful results of the global multicenter Phase III clinical trial HARMONi for the dual antibody Ivorasi, which achieved its primary endpoint of progression-free survival (PFS) and showed a significant trend in overall survival (OS) benefits [2][10]. Market Weekly Review - The pharmaceutical and biotechnology sector rose by 2.21% from May 26 to May 30, outperforming the Wind All A index (-0.02%) and the CSI 300 index (-1.08%) [7][9]. - The best-performing sub-sectors included other biological products (4.65%), chemical preparations (4.27%), and medical research outsourcing (4.0%), while offline pharmacies saw a decline of 2.69% [7][8]. - Notable individual stock performances included Shuyou Shen (60.4%), Huason Pharmaceutical (42%), and Changshan Pharmaceutical (35.9%) with declines seen in Haichen Pharmaceutical (-19.3%), Haishen Pharmaceutical (-11.9%), and Yixintang (-11.2%) [7][10]. Industry News and Key Company Announcements - The report highlights significant industry events, including the announcement by Summit Therapeutics regarding the successful results of the HARMONi study for Ivorasi, which is expected to support its application for a biological product license in the treatment of EGFR mutation non-small cell lung cancer [10][11]. - It also notes the collaboration between Innovent Biologics and AstraZeneca for the development of a new generation antibody-drug conjugate targeting CLDN18.2, with an upfront payment of $130 million and potential milestone payments totaling up to $1.34 billion [12][13]. - The report mentions various company announcements, including the conditional approval of innovative drugs by companies like Hengrui Medicine and the successful completion of clinical trials for several new therapies [13][14].

Investment Rating - The report provides a positive outlook on the TMT sector, suggesting a focus on the recovery of overseas AI chain valuations [3]. Core Insights - Nvidia's B series shipments exceeded expectations, with Q1 FY26 revenue reaching $44 billion, surpassing guidance of $43 billion. The company anticipates Q2 FY26 revenue guidance of $45 billion (±2%). The acceleration in B series shipments is expected to boost the industry's overall outlook, particularly for domestic Nvidia supply chain companies [3]. - The DeepSeek-R1 model update has significantly improved reasoning performance, placing it among the top tier globally. The new model shows a 20% and 15% improvement in mathematical and programming capabilities, respectively, while still having limitations in multimodal recognition [3]. - The domestic EDA (Electronic Design Automation) industry is expected to accelerate its localization process due to potential service halts from U.S. semiconductor software suppliers. This could lead to increased market share for domestic companies [3]. Market Weekly Review - The TMT sector's performance from May 26 to May 30 showed a positive trend, with the computer sector up by 1.77%, media by 1.74%, and communication by 1.53%. The overall TMT sector outperformed the CSI 300 index, which declined by 1.08% [3][5]. - The top-performing sub-industries included vertical application software and other computer equipment, both up by 3.01%, while the optical components and brand consumer electronics sectors faced declines of 2.99% and 1.84%, respectively [3][5]. Industry News and Key Company Announcements - The report highlights significant events in the AI sector, including the upcoming global AI technology conference and various product launches from major companies like Apple and Tesla [17]. - DeepSeek's R1 model has been updated, enhancing its reasoning capabilities and narrowing the gap with leading international models [19]. - The report notes that the Chinese government is actively promoting AI integration in industrial applications, with financial support for companies developing industry-leading AI models [22].